Strategies to develop therapeutic cancer vaccines for pancreatic cancer.

Personalized neoantigen vaccines, especially mRNA-based approaches, can elicit high-magnitude CD8+ T-cell responses and long-lived clonal persistence in postoperative PDAC.

• Why it matters: Pancreatic ductal adenocarcinoma (PDAC) has a low neoantigenicity and an immunosuppressive microenvironment, limiting the effectiveness of conventional immunotherapies and necessitating new strategies.
• What they did: A review of 120 clinical trials across various vaccine platforms, including cell-based, nucleic acid-based, and protein strategies, was conducted to assess feasibility, safety, and immune responses in PDAC.
• The result: While early-phase studies show feasibility and immune activation, durable clinical benefits remain rare; combining vaccines with other therapies and biomarker-driven trials may improve outcomes.